Huadong Medicine: Independent Financial Advisory Report of Guosheng Securities Co., Ltd. on the 2022 Restricted Stock Incentive Plan of Huadong Pharmaceutical Co., Ltd. on the adjustment of repurchase prices and the repurchase and cancellation of some restricted stocks

SZSI · May 31

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

华东医药：国盛证券有限责任公司关于华东医药股份有限公司2022年限制性股票激励计划调整回购价格及回购注销部分限制性股票事项之独立财务顾问报告

Huadong Medicine: Independent Financial Advisory Report of Guosheng Securities Co., Ltd. on the 2022 Restricted Stock Incentive Plan of Huadong Pharmaceutical Co., Ltd. on the adjustment of repurchase prices and the repurchase and cancellation of some restricted stocks

Risk Disclaimer

Statement